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ABSTRACT: Background: Identifying individ-
uals at risk of developing Parkinson’s disease (PD) is
critical to define target populations for future neuro-
protective trials.
Objective: The objective of this study was to apply the
PREDICT-PD algorithm of risk indicators for PD in a pro-
spective community-based study (the Bruneck study),
representative of the general elderly population.
Methods: PREDICT-PD risk scores were calculated
based on risk factor assessments obtained at baseline
(2005, n = 574 participants). Cases of incident PD were
identified at 5-year and 10-year follow-ups. Participants
with PD or secondary parkinsonism at baseline were
excluded (n = 35). We analyzed the association of
log-transformed risk scores with the presence of
well-established markers as surrogates for PD risk
at baseline and with incident PD at follow-up.
Results: A total of 20 participants with incident PD
were identified during follow-up (11 after 5 years and
9 after 10 years). Baseline PREDICT-PD risk scores
were associated with incident PD with odds ratios of
2.09 (95% confidence interval, 1.35–3.25; P = 0.001)
after 5 years and of 1.95 (1.36–2.79; P < 0.001) after
10 years of follow-up per doubling of risk scores. In
addition, higher PREDICT-PD scores were signifi-
cantly correlated with established PD risk markers
(olfactory dysfunction, signs of rapid eye movement
sleep behavior disorder and motor deficits) and signifi-
cantly associated with higher probability for prodromal
PD according to the Movement Disorder Society
research criteria at baseline.
Conclusions: The PREDICT-PD score was associ-
ated with an increased risk for incident PD in our
sample and may represent a useful first screening
step in future algorithms aiming to identify cases of
prodromal PD. © 2020 The Authors. Movement Dis-
orders published by Wiley Periodicals, Inc. on behalf
of International Parkinson and Movement Disorder
Society.
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The diagnosis of Parkinson’s disease (PD) is preceded
by a prodromal phase1,2 where neuropathology and neu-
ronal dysfunction have started in multiple sites of the cen-
tral and peripheral autonomic nervous system.3,4
Identifying patients in these earliest stages of the disease is
a key priority in current PD research and critical for the
implementation of future disease-prevention trials.5
A number of risk factors and prodromal symptoms of
PD have been identified,5 and a few algorithms to quan-
tify PD risk have been proposed, but their performance in
the general elderly population needs further study.2
The PREDICT-PD study algorithm is based on a
comprehensive meta-analysis of early nonmotor fea-
tures and risk factors.6 It was initially implemented in
an online cohort, showing an association with olfactory
performance, motor deficits, and signs of probable
rapid eye movement sleep behavior disorder (RBD) as
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disease-state surrogates in a cross-sectional analysis and
with incident PD during follow-up over 3 years with a
hazard ratio (HR) of 4.39 (95% confidence interval [CI],
1.03–18.68).7 A validation attempt in the population-
based Rotterdam study showed an association of the risk
score with incident PD with a HR of 1.30 that did not
significantly improve classification and discrimination
beyond age and sex.8
The simple, questionnaire-based approach of the
PREDICT-PD algorithm would make an attractive tool
for future population-based risk screening, Therefore,
we assessed the association of the PREDICT-PD algo-
rithm with incident PD in the longitudinal Bruneck
study cohort, a sample of the general elderly popula-
tion, during an overall follow-up period of 10 years.
Methods
Study Design and Population
Assessments were carried out in the Bruneck study, a
prospective population-based study on cardiovascular
and neurological diseases initiated in 1990.9,10 Their
follow-up assessment of 2005 included early nonmotor
features and risk markers10 required for the PREDICT-
PD algorithm and was used as a baseline for this analy-
sis. The study was approved by the local institutional
review board. All participants gave written informed
consent, and the assessments were carried out in accor-
dance with the Declaration of Helsinki.
Baseline and Follow-Up Assessments
In 2005, 574 participants (aged 55–94 years) under-
went a standardized interview and neurological exami-
nation including the Unified PD Rating Scale motor
section (UPDRS Part III). Medical history, medication,
and family history with a focus on movement disorders
and possible causes for secondary parkinsonism were
recorded. Assessments were performed by 2 neuro-
logists with special expertise in the field of movement
disorders.
Follow-up examinations took place in 2010 after a
median of 5.0 years (range, 4.9–5.0) and in 2016 after a
median of 10.4 years (range, 10.4–10.5). Assessments
followed a similar protocol as in 2005 and were performed
by 2 neurologists blinded to baseline risk markers. Incident
PD cases were identified as per UK PD Society Brain Bank
criteria.11 Data from 465 (86.3%) participants in 2010
and 341 (63.3%) in 2016 were available for analysis.
For a detailed flowchart of the study population
including deceased participants and differences of par-
ticipants according to follow-up status, see Supplemen-
tary Figure 1 and Supplementary Table 1.
Ascertainment of early Nonmotor Features and
PD Risk Markers
Following factors for the calculation of the PREDICT-PD
algorithm were available: age, sex, smoking status, coffee
use, hypertension, use of nonsteroidal anti-inflammatory
drugs, calcium channel blockers, beta blockers, alcohol
consumption, constipation, depression and/or anxiety,
known history of head injury, and a first-degree relative
with history of PD (Table 1). Application of the algorithm
was performed analogous to the description in the original
publication of the PREDICT-PD score.12
The following established risk markers (“intermedi-
ate” surrogate outcomes in the original PREDICT-PD
study)12 were available: olfactory loss, assessed with
the 12-item sniffin’ sticks identification test; probable
RBD, assessed throughout the RBD Screening Ques-
tionnaire; possible subthreshold parkinsonism using the
motor section of the UPDRS (Part III); and substantia
nigra (SN) echogenicity on transcranial sonography.
The distribution of these risk markers and of the Move-
ment Disorder Society (MDS) research criteria for pro-
dromal PD13 at the same time point in the Bruneck
cohort and their performance in predicting incident
cases of PD is published elsewhere.10,14
TABLE 1. Participant’s characteristics at baseline
Factor
All Participants,
n = 539
Incident PD,
n = 20
Predefined
RR/OR
from
Systematic
Review6
Agea 69.1 ± 9.4
67.2 (61.4–76.2)
70.2 ± 7.1
70.5 (63.4–76.2)
See
Methods
section
Femaleb 290 (53.7%) 9 (45.0%) 0.67
Smokerb
Current 73 (13.5%) 2 (10.0%) 0.44
Former 162 (30.0%) 8 (40.0%) 0.78
Never 305 (56.5%) 10 (50.0%) 1.00
Coffee useb 466 (86.3%) 18 (90.0%) 0.67
Hypertensionb 385 (71.3%) 14 (70.0%) 0.74
NSAID useb 56 (10.4%) 0 (0.0%) 0.83
CCB useb 72 (13.3%) 3 (15.0%) 0.90
Alcoholb 351 (65.0%) 14 (70.0%) 0.90
Beta blocker
useb
74 (13.7%) 1 (5.0%) 1.28
Head injuryb 40 (7.4%) 1 (5.0%) 1.58
Depression/
anxietyb
88 (16.3%) 7 (35.0%) 1.86
Constipationb 86 (15.9%) 5 (25.0%) 2.34
Family history
of PDb
41 (7.6%) 5 (25.0) 4.45
aQuantitative results are reported in mean with standard deviation and
medians (25th–75th percentile).
bBinominal variables are given in number and percentage of the respective
category.
PD, Parkinson’s disease; RR, risk ratio; OR, odds ratio; NSAID, nonsteroidal
anti-inflammatory drugs; CCB, calcium channel blocker.
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A detailed description of the ascertainment of all
markers and respective cut-offs is available in the Sup-
plementary Methods.
Statistical Analysis
As nonnormal distributions for continuous quantita-
tive variables were shown throughout, group compari-
sons were performed with the Mann-Whitney U test.
Significance levels for binary data were assessed with the
chi-square test. Cross-sectional correlation analysis
between log2-transformed risk scores (expressed as odds)
and established PD risk markers at baseline was per-
formed using the Spearman rank test. The predictive
value of the risk scores for cases of incident PD at
follow-up was examined using binary logistic regression
analysis for the PREDICT-PD log odds, and the results
are given in odds ratios (ORs) and 95% CIs. Log2-
transformation was used following the example of the
original PREDICT-PD cohort in order to render results
comparable and allow better interpretation of risk esti-
mates. Statistical analysis was performed using SPSS ver-
sion 24 for Windows (IBM Corp., Armonk, NY). The
significance level was set at a 2-sided P value of ≤0.05.
Results
Of the 574 baseline participants, 35 had idiopathic
PD or secondary parkinsonism and were excluded from
the analysis. Table 1 depicts characteristics of the
remaining 539 included participants. In the cross-sec-
tional correlation analysis between established PD risk
markers and risk scores we found a weak but signifi-
cant correlation of PREDICT-PD risk scores with the
sniffin’ sticks identification test scores (rs = −0.186,
P < 0.001), RBD Screening Questionnaire scores
(rs = 0.180, P < 0.001), and UPDRS Part III scores (rs
= 0.176, P < 0.001) (Supplementary Fig. 2), but not
with SN echogenicity. In addition, the PREDICT-PD risk
scores were significantly higher in the participants with a
higher probability of prodromal PD as per MDS
research criteria (e.g. 1:33 [1:89–1:17] for those with
probabilities above the cut off of ≥80% versus 1:110
[1:207–1:63] for those with <80% probability for pro-
dromal PD, P = 0.001; Supplementary Table 2).
A total of 20 participants were identified with inci-
dent PD at follow-up, 11 after 5 years and 9 after
10 years. Baseline PREDICT-PD risk scores were signif-
icantly higher in the participants with PD after 5 years
and for the whole 10-year period of follow-up (Table 2).
Baseline PREDICT-PD risk scores were associated with
incident PD with ORs of 2.09 (95% CI, 1.35–3.25;
P = 0.001) after 5 years and of 1.95 (95% CI,
1.36–2.79; P < 0.001) after 10 years of follow-up per
the doubling of risk scores. The results remained signifi-
cant even when using risk scores without age and sex
(Supplementary Table 3).
Discussion
In this study, we applied the PREDICT-PD algorithm,
a simple questionnaire-based screening tool aiming to
identify participants with increased PD risk in a longi-
tudinal sample of the general elderly population. The
PREDICT-PD study first employed the algorithm in an
online cohort with follow-ups for future PD diagnosis
over 3 years, where it predicted incident PD with a HR
of 4.39 and correlated with established markers of PD.7
An application of this score performed in a longitudinal
sample of the population-based Rotterdam study
showed an association of the risk score with incident
PD with a HR of 1.30 that did not significantly
improve classification and discrimination beyond age
and sex.8 However, several factors were missing from
their calculations or assessed with surrogate markers
(eg, constipation). As the scales used for HR calculation
in these 2 applications differed (log odds of risk scores
TABLE 2. Distribution of baseline risk scores and association with incident PD at follow-ups
Follow-Up Incident PD/PD Free, n
PREDICT-PD Risk
Scores of PD-Free
Participantsa
PREDICT-PD Risk
Scores of Incident
PD Casesa P Valueb
Log Risk Given in OR (95% CI)c
P Value
Baseline 0/539 1:109 (1:204–1:62) – – –
0–5 y 11/451 1:116 (1:222–1:70) 1:44 (1:131–1:19) 0.007 2.09 (1.35–3.25);
0.001
5–10 y 9/321 1:141 (1:270–1:81) 1:76 (1:161–1:53) 0.094 1.50 (0.88–2.54)
0.134
0–10 y 20/321 1:141 (1:270–1:81) 1:71 (1:128–1:31) 0.001 1.95 (1.36–2.79)
< 0.001
aDistribution of PREDICT-PD odds is given in median with 25th and 75th confidence intervals.
bSignificance levels for distributions of risk scores were calculated using the Mann-Whitney U test as data were not normally distributed.cBinary logistic regression
analysis of log odds was used to calculate ORs and 95% CIs. ORs are given for a 1-unit change in log risk scores.
PD, Parkinson’s disease; OR, odds ratio; CI, confidence interval.
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vs. transformation of risk scores in z scores), a direct
comparison of HRs is difficult.
In our sample, we found a significant association of
higher risk scores at baseline with a future diagnosis of PD
with an OR of 2.09 after 5 and 1.95 after 10 years of
follow-up. These results survived even after omitting age
and sex from the score, which is encouraging in light of the
ambiguous results in the Rotterdam study. In addition, risk
scores significantly correlated with established PD risk
markers (olfactory dysfunction, signs of probable RBD,
and subtle motor impairment) and were associated with
higher posttest probability for prodromal PD as per MDS
research criteria at baseline. It should be noted that our data
do not allow calculation of HR, as the exact time of conver-
sion was unknown because of the 5-year follow-up inter-
vals. However, OR and HR can be comparable at a low
incidence rate,15,16 which is the case in our cohort and the
original PREDICT-PD cohort. The difference in magnitude
of risk estimates in the original PREDICT-PD online cohort
compared with the Bruneck cohort (HR 4.39 vs. OR 2.09)
might be explainable because of the rather wide but over-
lapping CIs related to the small number of PD cases in both
samples, different follow-up times, and differences in
recruitments (online cohort in PREDICT-PD vs. unselected
elderly sample).
Distribution of the various risk markers and early non-
motor features as well as age and sex were mostly compa-
rable with the original cohort studied by Noyce and
colleagues.12 Differences were observed for positive family
history for PD (8% vs. 20%), which might reflect differ-
ences in the recruitment strategy between both studies.
A positive family history of PD has been found in approxi-
mately 4% of unselected population samples,17 similar to
the Bruneck study. Baseline hypertension was much more
common in this population compared with the PREDICT-
PD study (76% vs. 25%). The Bruneck study used a
precise definition of hypertension based on self-reported
diagnosis and concomitant medication against hyperten-
sion as well as 3 separate blood pressure recordings at base-
line (see Supplementary Methods), and its prevalence is in
line with the results of other population-based cohorts.18
An interesting detail concerns the prediction differ-
ences for converters identified after the first as compared
with the second 5-year interval. The OR for this second
group was slightly lower at 1.50 and not statistically sig-
nificant. This observation could point to a declining pre-
dictive accuracy of the model over time and is in line
with the fact that different prodromal nonmotor and
motor manifestations occur at different time intervals
prior to the onset of motor symptoms.2 As the time of
onset of defining motor features of PD approaches, more
prodromal markers will have developed such that the
identification of true cases of prodromal PD will become
more accurate closer to the clinical onset of disease.
The PREDICT-PD score was developed as an online
tool only including items that can be assessed remotely
and therefore does not require in-person examinations. It
did not include the established and stronger “intermedi-
ate” markers shown to clearly associate to a substantially
increased PD risk2,14 that could theoretically also be
remotely assessed. Instead, these markers were used in the
original publication as surrogate markers until sufficient
incident cases had occurred during the follow-up of
3 years, but the group very recently reported that the
inclusion of these markers into an updated algorithm may
boost its performance.19 The PREDICT-PD approach
models risk as a continuum of odds rather than a proba-
bility and in that way differs from the Movement Disor-
der Society prodromal PD score. The latter also includes
other factors that can only be assessed in person including
clinical examination by trained health professionals
(eg, the UPDRS), sonography, or DAT-SPECT.20 Its pre-
dictive value has been evaluated in several different
cohorts.10,21,22 In contrast, the PREDICT-PD score may
serve as a simple first screening step that could also be
used online, filtering participants suitable for further in-
person assessments. Participants with an elevated risk
may then consecutively be invited for further assessment
steps of increasing specificity, aiming to identify those
who will finally go on to develop PD. Such assessments
may include genetic testing, polysomnography, trans-
cranial sonography, or dopamine transporter imaging,
which are more costly and time-consuming. They may
therefore only be used in a more defined group of partici-
pants, as envisaged for future risk screening programs
such as in the Parkinson’s Progression Markers Initiative
(PPMI) 2.0 study.23
Our study has limitations. The small incidence of case
numbers leads to wide confidence intervals and may
also contribute to differences observed in risk estimates
of the first versus the second 5-year follow-up interval.
Despite the fact that established criteria for a PD diag-
nosis were applied by movement disorders specialists,
misdiagnosis cannot be excluded. The long follow-up
of 10 years in an unselected population-based sample
represents a strength of our study as does the in-person
assessments by movement disorder specialists blinded
to the baseline results, adding to the validity of this
analysis. Although our results support the usefulness of
the PREDICT-PD algorithm as a possible screening tool
for prodromal PD, large (online) studies will be needed
to finally determine its value.
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